We are live on ! Find out more
EPRS

Epirus Biopharmaceuticals
EPRS

Delisted

EPRS was delisted on the 3rd of August, 2016.

21 hedge funds and large institutions have $21.3M invested in Epirus Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
21
Holders Change
+21
Holders Change %
–
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
–
Reduced
–
Closed
–
Calls
$87​K
Puts
–
Net Calls
+$87​K
Net Calls Change
+$87​K

EPRS Hedge Fund Activity: Q3 2014 in Review

21 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Epirus Biopharmaceuticals (EPRS) for Q3 2014, worth a combined $21.3M.

Buyers outnumbered sellers: 21 funds opened new EPRS positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $19.2M.

  • 21 institutional investors held Epirus Biopharmaceuticals (EPRS) as of Q3 2014, up from 0 in Q2 2014.
  • Funds reported $21.3M of Epirus Biopharmaceuticals stock for Q3 2014.
  • 21 funds opened new Epirus Biopharmaceuticals positions in Q3 2014 and 0 closed out, a net change of +21 holders.
  • The largest Epirus Biopharmaceuticals buyer in Q3 2014 was TPG Group Holdings (SBS) Advisors, an estimated $19.2M added.

Based on aggregated 13F filings for Q3 2014.